1,2,3‐Triazole‐based esters and carboxylic acids as nonclassical carbonic anhydrase inhibitors capable of cathepsin B inhibition

Author:

Siwach Kiran1,Rani Manishita1,Vats Lalit12,Giovannuzzi Simone3,Paul Avijit Kumar4,Brahma Mettle5,Kumari Neetu5,Maruthi Mulaka5,Raghav Neera1,Supuran Claudiu T.3,Sharma Pawan K.16

Affiliation:

1. Department of Chemistry Kurukshetra University Kurukshetra Haryana India

2. Department of Chemistry Government College Bherian, Pehowa Kurukshetra Haryana India

3. Neurofarba Department, Pharmaceutical and Nutraceutical Section University of Florence Florence Italy

4. Department of Chemistry National Institute of Technology Kurukshetra Haryana India

5. Department of Biochemistry Central University of Haryana Mahendergarh India

6. Department of Chemistry Central University of Haryana Mahendergarh India

Abstract

AbstractHerein, we report the design and synthesis of a library of 28 new 1,2,3‐triazole derivatives bearing carboxylic acid and ester moieties as dual inhibitors of carbonic anhydrase (CA) and cathepsin B enzymes. The synthesised compounds were assayed in vitro for their inhibition potential against four human CA (hCA) isoforms, I, II, IX and XII. The carboxylic acid derivatives displayed low micromolar inhibition against hCA II, IX and XII in contrast to the ester derivatives. Most of the target compounds showed poor inhibition against the hCA I isoform. 4‐Fluorophenyl appended carboxylic acid derivative 6c was found to be the most potent inhibitor of hCA IX and hCA XII with a KI value of 0.7 μM for both the isoforms. The newly synthesised compounds showed dual inhibition towards CA as well as cathepsin B. The ester derivatives exhibited higher % inhibition at 10−7 M concentration as compared with the corresponding carboxylic acid derivatives against cathepsin B. The results from in silico studies of the target compounds with the active site of cathepsin B were found in good correlation with the in vitro results. Moreover, two compounds, 5i and 6c, showed cytotoxic activity against A549 lung cancer cells, with IC50 values lower than 100 μM.

Publisher

Wiley

Subject

Drug Discovery,Pharmaceutical Science

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3